Under new leadership, Novartis' Sandoz unit breaks up with digital therapeutics outfit Pear
Looks like Novartis’ Sandoz unit — under new leadership — has severed ties with Pear Therapeutics, dissolving the partnership that was inked in 2018.
Last year, Sandoz and Pear collaborated on and launched reSET, an FDA-approved digital therapeutic designed to deliver cognitive behavioral therapy over 12 weeks to patients with substance abuse disorder (SUD) who are in outpatient treatment under the supervision of a doctor. The Swiss drugmaker also invested in Pear’s Series B round of financing announced in January 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.